Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jan 12;212(3):367–377. doi: 10.1093/infdis/jiv005

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

PMC Copyright notice

Figure 2. — Patient-reported outcomes throughout treatment with sofosbuvir/ribavirin in patients coinfected with human immunodeficiency virus and hepatitis C virus (HCV) and matched controls with HCV monoinfection. The physical component summary (PCS) score is significantly lower in HIV/HCV-coinfected patients, compared with HCV-monoinfected patients (P < .05) at baseline, 12 weeks after treatment cessation in those who achieved sustained virologic response (SVR12); mental component summary at posttreatment week 4; fatigue scale at SVR12; total Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire baseline, SVR12; Chronic Liver Disease Questionnaire–Hepatitis C Virus (CLDQ-HCV) instrument at SVR12; work productivity and activity impairment of Work Productivity and Activity–Specific Health Problem (WPAI:SHP) questionnaire are similar between HIV/HCV-coinfected patients and HCV-monoinfected subjects at all time points (all P > .05). Abbreviations: AI, activity impairment; FS, fatigue scale; WI, work productivity impairment.